Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program

PharmacoEconomics

Volumn 30, Issue 4, 2012, Pages 337-353

  Demarteau, Nadia ^a   Breuer, Thomas ^a   Standaert, Baudouin ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Budget impact analysis; Cervical cancer; Cervical smear; Cost effectiveness; Human papillomavirus infections; Modelling; Papillomavirus vaccines Screening

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; BRAZIL; BUDGET; CANCER EPIDEMIOLOGY; CANCER MODEL; CANCER PREVENTION; CANCER SCREENING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HIDDEN MARKOV MODEL; HUMAN; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RESOURCE MANAGEMENT; SENSITIVITY ANALYSIS; UNITED KINGDOM; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; AGED; BRAZIL; CHILD; FEMALE; HUMANS; MARKOV CHAINS; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TIME FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84858220712     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11591560-000000000-00000     Document Type: Article

References (48)

1. Cancer Research UK. Cervical cancer-UK incidence statistics online. Available from URL: http://info.cancer researchuk.org/cancerstats/types/cervix/ incidence/index.htm Accessed 2010 Jul 26
2. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008: cancer incidence, mortality and prevalence worldwide in 2008 online. Available from URL: http://globocan.iarc.fr Accessed 2010 Jun 22
3. Antilla A, Aoki D, Arbyn M, et al. Cervix cancer screening. Lyon: IARC Press, 2005. Report no.: 10
4. Arbyn M, Raifu AO, Autier P, et al. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007 Apr 10; 18 (10): 1708-15 (Pubitemid 47506260)
5. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: screening for cervical cancer in developing countries. Vaccine 2006 Aug 31; 24 Suppl. 3: S3/71-7
6. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189 (1): 12-9 (Pubitemid 29406813)
7. zur Hausen H. Intracellular surveillance of persisting viral infections: human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet 1986 Aug 30; 328 (8505): 489-91
8. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007 Apr 2; 121 (3) 621-632 (Pubitemid 46986496)
9. Munoz N, Castellsague X, de Gonzalez AB, et al. HPV in the etiology of human cancer. Vaccine 2006 Jun 23; 24 Suppl 3 S1-3 10
10. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by onco-genic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009 Jul 25; 374 (9686) 301-314
11. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006 Dec 4; 95 (11): 1459-66 (Pubitemid 44863348)
12. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007 May 10; 356 (19): 1915-27
13. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007 May 10; 356 (19): 1928-43 (Pubitemid 46740303)
14. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004 Nov 13; 364 (9447): 1757-65 (Pubitemid 39488060)
15. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst 2010 Feb 5; 102 (5): 325-39
16. Szarewski A. HPV vaccine: cervarix. Expert Opin Biol Ther 2010 Mar; 10 (3): 477-87
17. Skinner R, Apter D, Chow SN, et al. Cross-protection efficacy of Cervarix™ against oncogenic HPV types beyond HPV-16/18 abstract no. O-29.01 25th International Papillomavirus Conference; 2009 May 8-14; Malmo
18. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009 Apr 1; 199 (7): 926-35
19. Brabin L, Roberts SA, Stretch R, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008; 336 (7652): 1056-8 (Pubitemid 351692248)
20. Stokley S, Dorell C. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2010 Sep 18; 58 (36): 997-1001
21. Wong C, Berkowitz Z, Wai Lee J, et al. National HPV vaccine uptake and vaccination predictors and barriers for girls 8-17 years old-United States, 2008. National STD Prevention Conference; 2010 Mar 8-11; Atlanta (GA) online. Available from URL: http://cdc.confex.com/cdc/std 2010/webprogram/Paper22960. html Accessed 2010 Jul 19
22. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12 (5-6): 343-51
23. Kim JJ, Brisson M, Edmunds WJ, et al. Modeling cervical cancer prevention in developed countries. Vaccine 2008 Aug 19; 26 Suppl. 10: K76-86
24. Marra F, Cloutier K, Oteng B, et al. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27 (2): 127-47
25. Suarez E, Smith JS, Bosch FX, et al. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 2008 Sep 15; 26 Suppl. 5: F29-45
26. Adang E Voordijk L Jan van der Witt G et al Costeffectiveness analysis in relation to budgetary constraints and reallocative restrictions Health Policy 2005 Oct 74 2 146-156 (Pubitemid 41253718)
27. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999 Jun; 18 (3) 341-364 (Pubitemid 29242816)
28. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 2006 May; 62 (9)2091-2100
29. Hutubessy RC, Bendib LM, Evans DB. Critical issues in the economic evaluation of interventions against communicable diseases. Acta Trop 2001 Mar 30; 78 (3): 191-206 (Pubitemid 32322472)
30. World Health Organization. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: WHO, 2003
31. Drummond MF. Principles of economic appraisal in health care. Oxford: Oxford University Press, 1980
32. Earnshaw SR, Richter A, Sorensen SW, et al. Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making 2002 Sep; 22 (5 Suppl.): S80-91
33. Epstein DM, Chalabi Z, Claxton K, et al. Efficiency, equity, and budgetary policies: informing decisions using mathematical programming. Med Decis Making 2007 Mar; 27 (2): 128-37 (Pubitemid 46568911)
34. Stinnett AA, Paltiel AD. Mathematical programming for the efficient allocation of health care resources. J Health Econ 1996 Oct; 15 (5) 641-653 (Pubitemid 26423356)
35. Earnshaw SR, Hicks K, Richter A, et al. A linear programming model for allocating HIV prevention funds with state agencies: a pilot study. Health Care Manag Sci 2007 Sep; 10 (3): 239-52
36. Richter A, Hicks KA, Earnshaw SR, et al. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy 2008 Sep; 87 (3): 342-9
37. Weniger BG Chen RT Jacobson SH et al Addressing the challenges to immunizationractice with an economic algorithm for vaccine selection Vaccine 1998 Nov 16 19 1885-1897 (Pubitemid 28473931)
38. Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics 2003; 21 (12): 839-51 (Pubitemid 37056051)
39. Luenberger DG, Yinyu Y. Linear and nonlinear programming. 3rd ed. New York: Springer, 2008
40. Debicki D, Ferko N, Demarteau N, et al. Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 2008 Sep 15; 26 Suppl. 5: F16-28
41. Colantonio L, Gomez JA, Demarteau N, et al. Costeffectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009; 27 (40): 5519-29
42. Castellsague X, de Sanjose S, Aguado T, et al. HPV and cervical cancer in the world: 2007 report. Vaccine 2007; 25 Suppl. 3: C1-230
43. Tjalma W, Paavonen J, Naud P, et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histopathological lesions in an oncogenic HPV-naive population abstract no. A-171-0004-01446. 16th International Meeting of the European Society for Gynaecological Oncology (ESGO); 2009 Oct 11-14 Oct; Belgrade
44. Department of Health. Cervical screening programme, England: 2003-2004 online. Available from URL: http://www.dh.gov.uk/assetRoot/04/09/63/75/04096375. pdf Accessed 2010 Jul 1
45. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-hpv-16 and-18 antibodies induced by vaccination with the as04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 2009 Feb; 115 (3 Suppl. 1): S1-S6
46. McKenna C, Chalabi Z, Epstein D, et al. Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. J Health Econ 2010 Jan; 29 (1): 170-81
47. Franco EL Cuzick J Cervical cancer screening followingrophylactic humanapillomavirus vaccination Vaccine 2008 Mar 14 26 Suppl 1 A16-1 A23 (Pubitemid 351312311)
48. Rogoza RM, Ferko N, Bentley J, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 2008 Sep 15; 26 Suppl. 5: F46-58